A Review on Analytical Method
Development and Validation for the Simultaneous Estimation of Levothyroxine and
Liothyronine in Combined Pharmaceutical Dosage Form by RP-HPLC
Mugdivari Sangeetha*, A.Swarna Mahalakshmi
CMR College of Pharmacy,
Kandlakoya, Medchal, Hyderabad, Telangana, India-501401.
*Correspondence: sangeetha.kodiganti@gmail.com
DOI: https://doi.org/10.71431/IJRPAS.2025.4906
|
Article Information
|
|
Abstract
|
|
Review Article
Received: 12/09/2025
Accepted: 24/09/2025
Published: 30/09/2025
Keywords
Levothyroxine; Liothyronine;
RP-HPLC; Simultaneous Estimation;
Method Development; Method Validation; ICH
Guidelines;
|
|
The simultaneous estimation of
Levothyroxine (T4) and Liothyronine (T3) in combined pharmaceutical dosage
formsis crucial for effective hypothyroidism management.Due totheir
lowconcentrations,structural similarity, and high potency, method development
poses analytical challenges. Reversed-phase high-performance liquid
chromatography (RP-HPLC) stands out as a preferred technique owing to its
high sensitivity, resolution, and reproducibility across a wide range of
compound polarities.
This review outlines RP-HPLC principles and
highlights method development strategies such as columns election, mobile
phase optimization, detection wavelength, and sample preparation. It also
discusses essential method validation parameters in line with ICH guidelines,
including accuracy, precision, specificity, linearity, LOD, LOQ, robustness,
and system suitability. Literature-based insights into validated methods for
routine analysis, stability studies, and pharmacokinetic evaluations are
presented.
Advancements such as
gradient elution, stability-indicating approaches, and mass spectrometry
integration are explored for their impact on method performance. The review
concludes with clinical and regulatory perspectives, reinforcing RP-HPLC as a
reliable tool for the quantitative analysis of thyroid hormones in
pharmaceutical formulations.
|
INTRODUCTION
High-Performance Liquid Chromatography (HPLC) is a
pivotal analytical tool extensively used in pharmaceutical analysis due to its
remarkable efficiency, precision, and versatility. Among its various forms,
Reversed-Phase HPLC (RP-HPLC) is particularly favored for its ability to
effectively separate and quantify compounds across a wide polarity range. The
fundamental principle of RP-HPLC is based on hydrophobic interactions between
the analyte and the non-polar stationary phase, typically consisting of C18
bonded silica. In contrast, the mobile phase is polar , often comprising
mixtures of water with organic solvents such as methanol or acetonitrile.
Compounds with greater hydrophobicity tend to interact more strongly with the
stationary phase, resulting in longer retention times and better separation.
RP-HPLC offers several advantages, including its
versatility in handling a wide variety of pharmaceutical and biomolecular
substances, high resolution that produces sharp and well-defined chromatographic
peaks, excellent reproducibility essential for quality control applications,
and high sensitivity which is crucial for the detection of low-dose drugs,
particularly those administered in microgram quantities. In pharmaceutical
applications, RP-HPLC plays a vital role in the assay of active pharmaceutical
ingredients (APIs) to ensure correct dosage, in purity testing for identifying
impurities and degradation products, in dissolution testing to assess drug
release from dosage forms, and in bioequivalence studies that compare the
bioavailability of different formulations.
The simultaneous analysis of Levothyroxine (T4) and
Liothyronine (T3), two synthetic thyroid hormones, presents analytical
challenges owing to their structural similarity, extremely low dosage levels,
and potential interference from endogenous thyroid hormones in biological
matrices. RP-HPLC, with its high resolution and sensitivity, provides an ideal
analytical approach to accurately and reliably estimate these hormones simultaneously
in combined pharmaceutical formulations, thus ensuring therapeutic efficacy and
regulatory compliance.
DRUG PROFILE OF
LEVOTHYROXINE & LIOTHYRONINE
LEVOTHYROXINE
Generic Name: Levothyroxine Sodium
Description: Levothyroxine is the synthetic form of thyroxine
(T4), a naturally occurring thyroid hormone secreted by the thyroid gland. It
plays a crucial role in regulating metabolism, growth, and development.
Levothyroxine is used to treat hypothyroidism (underactive thyroid) and other
thyroid-related disorders.
Solubility: Practically insoluble in water and alcohol;
slightly soluble in alkali solutions and very slightly soluble in glycerol.
Soluble in 1N NaOH and 1N KOH.
Melting Point: Approximately 235°C (decomposes at high
temperatures).
Molecular Formula: C15H11I4NO4
Molecular Structure:
Chemical Name:
(2S)-2-Amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic
acid
Mechanism of Action:
Levothyroxine acts as a synthetic replacement for the
endogenous hormone thyroxine (T4). It is converted peripherally to
triiodothyronine (T3), the active form, which binds to thyroid hormone
receptors in the nucleus and regulates gene expression. This affects protein
synthesis and increases basal metabolic rate, influencing the metabolism of
carbohydrates, fats, and proteins.
Clinical Applications: Used in the treatment of
hypothyroidism, goiter, and as part of thyroid cancer management.
LIOTHYRONINE
Generic Name: Liothyronine Sodium
Description: Liothyronine is the synthetic form of
triiodothyronine (T3), the biologically active thyroid hormone. It is used
primarily in the treatment of hypothyroidism and ismore potent and
faster-actingthan Levothyroxine (T4). It regulates metabolic processes, protein
synthesis, and energy metabolism.
Solubility: Slightly soluble in water; soluble in dilute
alkali and alcohol. Melting Point: Approximately205°C (decomposes at higher
temperatures) Molecular Formula: C15H12I3NO4
Molecular Structure:
Chemical Name:
(2S)-2-Amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoic
acid
Mechanism of Action:
Liothyronine mimics the action of endogenous
triiodothyronine (T3). It enters cells and binds to thyroid hormone nuclear
receptors, modulating gene expression involved in growth, development, and
metabolism. It increases the basal metabolic rate and affects the metabolism of
proteins, carbohydrates, and lipids. It has a quicker onset and shorter
half-life compared to Levothyroxine.
Clinical Applications: Employed in the management of
hypothyroidism, myxedema coma, and as a diagnostic agent in thyroid function
tests.
LITERATURE
REVIEW
The simultaneous estimation of Levothyroxine (T4) and
Liothyronine (T3) using RP-HPLC has been extensivelystudied, with various
methodologies developed to enhance sensitivity, specificity, and efficiency.
|
AUTHOR
(YEAR)
|
JOURNAL
NAME
|
TITLE
OF ARTICLE
|
ANALYTICAL
CONDITIONS
|
APPLICATIONS
|
|
Jaina Anusha et al. (2024)
|
Zenodo / Research
Gate
|
Method Development and Validation for the
Simultaneous Estimation of
Levothyroxine and Liothyronine in Bulk and Pharmaceutical Dosage Forms by RP-HPLC
|
Column: Agilent Zorbax C18
Mobile Phase: Methanol: Acetonitrile (25:75 v/v)
Detection: 265 nm Retention
time: < 8 min Linearity: T4 (100–500 μg/mL),
T3(30–70μg/mL)
|
Routine QC of combined dosage forms
|
|
Rapaka et al. (1981)
|
Journal of Pharmaceutical
Sciences
|
Dissolution and Content Uniformity of
Liothyronine Sodium and Levothyroxine Sodium Tablets
|
RP-HPLC technique; Early
development study—specific details not widely available. focused on content
uniformity and dissolution testing
|
Baseline study for method development
|
|
Abhay Kumar Rai et al. (2024)
|
Asian Journal of Biological and Life
Sciences
|
Simultaneous Estimation Method Development and
Validation of Levothyroxine and Liothyronine by HPLC Method
|
Column:PhenomenexC18 Mobile
Phase: Acetonitrile :Water(25:75)
Detection: 300 nm
RetentionTime:T4=2.08 min, T3 = 5.05 min
|
Stability testing and dosage analysis
|
|
Abhay Kumar Rai et al. (2024)
|
Asian Journal of Biological and Life
Sciences
|
Analytical Validation of Stability-Indicating Reverse Phase HPLC
Method for Simultaneous Estimation
of Levothyroxine and
Liothyronine
|
Column:PhenomenexC18; Mobile
Phase: Acetonitrile:Water(25:75), pH adjusted to 6.0 Detection: 285 nm;
Retention Time: T4 = 2.08 min, T3 = 5.02 min
|
Stability studies and forced degradation
|
|
Rohit Dutt et al. (2020)
|
Drug Delivery Journal
|
Development and Validation of UPLC- MS/MS
Method for Rapid Simultaneous Determination of Levothyroxine and
Liothyroninein Human Serum
|
Column:HyPURITYC18 Detection:
ESI-MRM
Mobile Phase: Not specified
Linearity: T4 = 50.37–300.13 ng/mL,T3=0.5–50.37ng/mL Prep: Protein
precipitation
|
Pharmacokinetic and bioequivalence
studies
|
|
JW Collier et al. (2011)
|
International Journal of Pharmaceutical Sciences
|
A Selective and Sensitive Gradient HPLC
Method for Analysis of Levothyroxine Sodium Tablets
|
Column:Waters Nova-pak;
Mobile Phase: phosphate buffer pH 3.0: Methanol (55:45)
Detection:225nm
Gradient elution
|
Dissolution testing, product release
|
|
Gika et al. (2005)
|
Journal of
Chromatography
|
Validated HPLC Method For Determination of Iodotyrosines and Iodothyronines in
Biological Samples
|
Column:C18
Mobile Phase and gradient not
fully specified Detection:225nm
Used solid-phase extraction
for sample preparation
|
Biological and
pharmaceutical sample analysis
|
|
Bun evicius et al. (2002)
|
Journal of Clinical Endocrinology and Metabolism
|
Double-Blind Study of Thyroxine and
Triiodothyronine in Thyroidectomized
Patients
|
Clinical dosing protocol
Focused on pharmacodynamics and clinical responses of
Combined therapy
|
Evaluating
therapeutic efficacy of T4+ T3
|
|
Appelhof et al. (2005)
|
Journal of Clinical Endocrinology and Metabolism
|
Combined Therapy Versus Monotherapy in Primary Hypothyroidism: A Double-Blind Randomized Controlled Trial
|
Clinical trial
T4:T3dosinginvaryingratios
Evaluation based on mood, cognition, and hormonal levels
|
Optimizing therapy and patient outcome
|
|
Hennemann et al. (2004)
|
European Journal of Endocrinology
|
Pharmacokinetics and Patient Preferences
of a New Combined Preparation of Levothyroxine Plus Sustained-Release
Liothyronine
|
Clinical trial
Used sustained-release
Liothyronine + standard T4 Pharmacokinetic monitoring of serum T3/T4 levels
|
Personalized dosing and combination therapy
|
CONCLUSION
The simultaneous estimation of Levothyroxine and
Liothyronine using RP-HPLC is vital for quality control and therapeutic
monitoring in hypothyroid treatment. RP-HPLC offers high sensitivity, accuracy,
and reproducibility, making it ideal for analyzing these low-dose hormones in
combined dosage forms. Various validated methods in the literature demonstrate
reliable separation and quantification under optimized chromatographic
conditions. The reviewed studies also emphasize the importance of method
validation as per ICH guidelines to ensure regulatory compliance. Thus, RP-HPLC
continues to be a dependable tool in pharmaceutical analysis and clinical
research involving thyroid hormone therapies.
REFERENCES
1. Anusha,J., & Narasimhulu,
G.(2024).Method Development and Validation fortheSimultaneous Estimation of
Levothyroxine and Liothyronine in Bulk and Pharmaceutical Dosage Forms by
RP-HPLC. Zenodo/ Research Gate.
2. Rapaka, R. S., Peffley, J. J., Doran, T. C.,
& Rowe, T. (1981). Dissolution and content uniformity of liothyronine
sodium and levothyroxinesodium tablets. Journal of Pharmaceutical Sciences,
70(5), 559–561.
3. Rai, A. K., & Yadav, S. (2024).
Simultaneous Estimation Method Development and Validation of Levothyroxine and
Liothyronine by HPLC Method. Asian Journal of Biological and Life Sciences,
13(1), 120– 125.
4. Abhay Kumar Rai et al. (2024). Simultaneous
Estimation Method Development and Validation of Levothyroxine and Liothyronine
by HPLC Method. Asian Journal of Biological and Life Sciences.
5. Rai, A. K., & Yadav, S. (2024).
Analytical Validation of Stability-Indicating Reverse Phase HPLC Method for
Simultaneous Estimation of Levothyroxine and Liothyronine. Asian Journal of
Biological and Life Sciences, 13(1), 126–132.
6. Dutt, R., Kaul, R., Bhat, P. A., &
Verma, P. (2020). Development and validation of UPLC-MS/MS method for rapid
simultaneous determination of levothyroxine and liothyronine in human serum.
Drug Delivery, 27(1), 426–434.
7. Collier, J.W., Nasr, M.M., &Mehvar, R.
(2011). A selective and sensitive gradient HPLC methodfor analysis of
levothyroxine sodium tablets. International Journal of Pharmaceutical Sciences
and Research, 2(9), 2315–2320.
8. Gika, H. G., Samanidou, V. F.,
&Papadoyannis, I. N. (2005). Development and validation of a HPLC method
for the determination of iodotyrosines and iodothyronines in biological
samples. Journal of Chromatography B, 819(1), 57–64.
9. Bunevicius, R., Kazanavicius, G.,
Zalinkevicius, R., & Prange Jr, A. J. (2002). Effects of thyroxine as
compared withthyroxineplustriiodothyroninein patientswith hypothyroidism.The
New England Journal ofMedicine, 340(6), 424–429.
10. Appelhof, B. C., Fliers, E., Wiersinga, W. M.,
et al. (2005). Combined therapy versus monotherapy inprimary hypothyroidism: a
double-blind randomized controlled trial. Journal of Clinical Endocrinology
& Metabolism, 90(5), 2666–2674.
11. Hennemann, G., Docter, R., Friesema, E. C. H.,
De Jong, M., & Krenning, E. P. (2004). Pharmacokinetics and patient
preferences of a new combined preparation of levothyroxine plus
sustained-release liothyronine. European Journal of Endocrinology, 150(1),
113–120.
12. Abhay Kumar Rai et al. (2024). Analytical
Validation of Stability-Indicating Reverse Phase HPLC Method for Simultaneous
Estimation of Levothyroxine and Liothyronine. Asian Journal of Biological and
Life Sciences.
13. Rohit Dutt et al. (2020). Development and
Validation of UPLC-MS/MS Method for Rapid Simultaneous Determination of
Levothyroxine and Liothyronine in Human Serum. Drug Delivery Journal.
14. Bhadru B, Rao TR, Jadav B. 2023. UV
Spectrophotometric Method development and validation for Metformin
Hydrochloride in bulk and its tablet formulation. Chemistry Research Journal 8
(6), 10-15.
15. Bhadru VNB, Rao V. 2023. Simultaneous
estimation of Levodopa and Benserazide by using reverse phase High Performance
Liquid Chromatography in API and marketed formulation, International Journal of
Recent Advances in Multidisciplinary Research 10: 9020-9024.
16. Boggula SKN, Bhadru B, Pathakala N, Peddapalli
H. 2023. Method development and validation of RP-HPLC method for the estimation
of Tolvaptan in bulk and its tablet dosage form. European Chemical Bulletin, 12
(10):5158-5171.
17. Patel S, Soni P, Omray LK. 2023. Development
and validation of RP-HPLC method for simultaneous estimation of Metformin
Hydrochloride and Gliclazide in bulk and tablet formulation. International
Journal of Drug Delivery Technology. 13(2):483-487.
18. Pravalika M, Lavanya J. 2023. Analytical
method development and validation of simultaneous estimation of Mifepristone
and misoprostol in bulk drug and pharmaceutical dosage form by RP-HPLC method.
International Journal of Research and Analytical Reviews 10(4): 674-690.
19. Pravalika P, Jephthah G, Reddy AR, Rao TR.
2023. A New RP-HPLC method for estimation of Vericiguat in bulk drug and
pharmaceutical dosage form. Journal of Advanced Scientific Research 14
(09):37-43.
20. Reddy AR, Sushma G., Rama Rao T., Kalyan
Varma V, Neelaveni K. 2023. Method development and validation of Tivozanib By
RP-HPLC in bulk and pharmaceutical dosage forms. International Journal of
Advanced Research, 11:566-573.